Medpace Holdings Inc(MEDP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | - | P/E | 37.35 | EPS (ttm) | 18.04 | Insider Own | 18.79% | Shs Outstand | 27.9M | Perf Week | 8.25% |
| Market Cap | 18.85B | Forward P/E | 34.21 | EPS next Y | 7.98% | Insider Trans | -6.3% | Shs Float | 22.7M | Perf Month | 9.39% |
| Enterprise Value | 18.31B | PEG | 2.63 | EPS next Q | 4.83 | Inst Own | 89.1% | Short Float | 7.1% | Perf Quarter | 15.19% |
| Income | 0.52B | P/S | 6.64 | EPS this Y | 19.38% | Inst Trans | 2.43% | Short Ratio | 5.86 | Perf Half Y | 64.48% |
| Sales | 2.84B | P/B | 32.13 | EPS next 5Y | 12.99% | ROA | 25.54% | Short Interest | 1.61M | Perf YTD | 19.97% |
| Book/sh | 20.97 | P/C | 26.72 | EPS past 3/5Y | 28.02% 31.79% | ROE | 117.88% | 52W High | -1.57% ($684.52) | Perf Year | 12.96% |
| Cash/sh | 25.22 | P/FCF | 28.23 | Sales past 3/5Y | 20.12% 22.27% | ROIC | 70.84% | 52W Low | 80.64% ($373.00) | Perf 3Y | 169.21% |
| Dividend Est. | - | EV/EBITDA | 28.86 | EPS Y/Y TTM | 25.24% | Gross Margin | 28.18% | Volatility(W/M) | 4.88% 3.6% | Perf 5Y | 219.94% |
| Dividend TTM | - | EV/Sales | 6.45 | Sales Y/Y TTM | 20.35% | Oper. Margin | 21.39% | ATR (14) | 21 | Perf 10Y | 2244.43% |
| Dividend Ex-Date | - | Quick Ratio | 0.83 | EPS Q/Q | 25.63% | Profit Margin | 18.24% | RSI (14) | 68 | Recom | 2.94 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.83 | Sales Q/Q | 8.5% | SMA20 | 7.5% ($626.78) | Beta | 1.13 | Target Price | $674.75 |
| Payout | - | Debt/Eq | 0.29 | Earnings | 2026/10/21 | SMA50 | 9.58% ($614.88) | Rel Volume | 0.71 | Prev Close | $676.77 |
| Employees | 6200 | LT Debt/Eq | 0.25 | EPS/Sales Surpr. | 9.11% 0.21% | SMA200 | 27.52% ($528.38) | Avg Volume(3M) | 0.28M | Price | $673.79 |
| IPO | 2016/8/11 | Option/Short | Yes/Yes | Trades | 8940 | Volume | 195,691 | Change | -0.44% |
A U.S. contract research organization (CRO) that provides full-service, end-to-end clinical trial services—including the design, execution, and management of clinical studies—on behalf of pharmaceutical and biotech companies. The firm specializes in conducting clinical trials as an outsourced partner and primarily serves small- and mid-cap biotech companies.
Over the past 1 year, on the higher side
2% below its 1-year high.
Traded less than usual. That is 71% of its average volume.
MEDP makes money exceptionally well
Of every $100 in sales, $21.39 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +19.4% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $2,886. Peers typically go for $2,642. Compared with its own 5-year average, it is 24% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +219.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 89.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #13 of 44 in the industry
Based on market cap of $19B.
GH#12 Guardant Health Inc $24B PER - MEDP#13 Medpace Holdings Inc $19B PER 37.4 
RVTY#14 Revvity Inc $18B PER 76.9 
CRL#15 Charles River Laboratories International Inc $17B PER - 
ICLR#16 Icon Plc $14B PER 332.1 
FAQ
What kind of company is MEDP?
MEDP belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of MEDP?
The market cap of MEDP is approximately $18.8B, ranking 618 within its sector.
What is the P/E ratio of MEDP?
MEDP has a P/E ratio of approximately 37.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for MEDP?
MEDP has recorded a 52-week high of $684.52 and a low of $373.00.
